NOS1AP and type 2 diabetes mellitus: In addition, genetic studies have implied that the variations in NOS1AP are associated with reduced glucose lowering effect in sulfonylurea users as well as increased incidence of type 2 diabetes in patients taking calcium channel blockers [9, 10].